Audentes Therapeutics (BOLD) Tops Q3 EPS by 1c

Audentes Therapeutics (NASDAQ: BOLD) reported Q3 EPS of ($0.88), $0.01 better than the analyst estimate of ($0.89).

For earnings history and earnings-related data on Audentes Therapeutics (BOLD) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Marti Technologies (MRT) Misses Q2 EPS by 9c ; Offers Guidance
• S&P 500 may pull back before midterms, but Citi says buy the dip